In the long human struggle against cancer's silent advance, a new kind of vigilance is being tested — one that listens for molecular whispers in the blood before the body raises any alarm. The NHS has begun trialling a microRNA-based blood test developed by Xgenera, capable of detecting twelve cancers with reported 99% accuracy, backed by £2.4 million in government funding and the enrollment of 8,000 patients. The announcement was made in the shadow of Dame Deborah James, whose death from bowel cancer in 2022 became a rallying cry for earlier detection. If the verification phase holds, this te
NHS trials blood test that detects 12 cancers with 99% accuracy
Catch it as early as possible, so this government is taking urgent action
Mark
So this test measures something called microRNA. What makes that different from the way doctors currently screen for cancer?
Mimi
Most screening now relies on imaging—colonoscopies, mammograms—or waiting for symptoms to appear. This test looks for molecular signals in the blood itself, patterns that show up before a person feels anything. It's earlier in the disease process.
Luke
But we should be clear: the 99 percent accuracy figure comes from initial data, not from the verification trial that's just starting. Eight thousand patients will now be enrolled to see if those numbers hold up in real conditions.
Mark
Right. So this announcement is about funding the test to prove itself, not about it being ready for the NHS yet.
Mimi
Exactly. They're in the phase where they gather evidence for approval. It could take years. But the government is backing it because the early signals are strong.
Luke
And we don't know yet how many false positives it produces, or how it performs across different populations, or what happens when you scale it up. Those are the questions the trial will answer.
Mark
Why did they announce this at an event honouring Dame Deborah James?
Mimi
She died of bowel cancer at forty and spent her final years pushing for better screening and earlier detection. Bowel cancer is one of the twelve the test can identify. The government is saying: this is the kind of innovation she advocated for.
Luke
That's fair, but it's also worth noting that the test's ability to actually reduce deaths from bowel cancer depends on what happens after detection—whether the NHS can handle a surge in diagnoses, whether treatment improves outcomes. The test is only part of the picture.
Mark
So the real work comes after the trial?
Mimi
Yes. Validation is step one. Then implementation, training, integration into the NHS system. Then measuring whether it actually saves lives.
Luke
And whether it's equitable—whether it reaches the people who need it most.
Il Polso
- Cancer kills partly because it hides — and a blood test that can find twelve types before a single symptom appears represents a fundamental challenge to that advantage.
- The UK's cancer survival rates lag behind comparable nations, and long diagnostic waiting lists mean the window for effective treatment is too often missed.
- £2.4 million in government funding is now moving the Xgenera test into a rigorous verification phase, with 8,000 patients enrolled to determine whether early results survive real-world scrutiny.
- Health Secretary Wes Streeting framed the investment as central to a national cancer plan aimed at making detection earlier, faster, and cheaper than current invasive methods allow.
- The trial carries personal as well as scientific stakes — announced at a ceremony honouring Dame Deborah James, whose advocacy for bowel cancer awareness shaped public and political will alike.
- Cautious optimism prevails: the technology is promising, but approval for NHS-wide use depends entirely on what the verification data reveals.
In the long human struggle against cancer's silent advance, a new kind of vigilance is being tested — one that listens for molecular whispers in the blood before the body raises any alarm. The NHS has begun trialling a microRNA-based blood test developed by Xgenera, capable of detecting twelve cancers with reported 99% accuracy, backed by £2.4 million in government funding and the enrollment of 8,000 patients. The announcement was made in the shadow of Dame Deborah James, whose death from bowel cancer in 2022 became a rallying cry for earlier detection. If the verification phase holds, this test may quietly rewrite the moment at which medicine first meets the disease.
The NHS is trialling a blood test that its developers say can detect twelve different cancers before symptoms appear. Created by biotechnology company Xgenera, the test measures microRNA — molecules central to how cancer develops — in a blood sample, then uses artificial intelligence to identify whether cancer is present and where. Early data points to 99% accuracy across cancers including lung, bowel, pancreatic, ovarian, and brain tumours, among others.
The government has committed £2.4 million through the National Institute for Health and Care Research to fund the next stage of development. Around 8,000 patients will take part in the verification and validation phase — the evidence-gathering process required before any test can be approved for NHS use. Health Secretary Wes Streeting made the announcement at an event renaming a cancer research laboratory in memory of Dame Deborah James, the broadcaster and campaigner who died of bowel cancer in 2022 aged 40.
Streeting positioned the investment within a broader national cancer strategy, acknowledging the strain of long waiting lists and the lives lost when diagnosis comes too late. Bowel cancer — one of the twelve the test targets — is the UK's second leading cause of cancer death, and a non-invasive blood test capable of catching it early would mark a significant departure from current screening methods.
Professor Lucy Chappell of the NIHR described the test as heralding "an exciting new era in cancer detection," while maintaining that the verification phase will be decisive. Dame Deborah's father, Alastair James, attended the announcement and reflected on his daughter's participation in trial treatments and her lifelong push for better detection. He echoed her signature public health appeal and framed the trial as an effort to give those touched by cancer more time — a sentiment that gives this scientific milestone its unmistakable human weight.
The NHS is moving forward with trials of a blood test that its developers say can identify twelve different cancers before a person shows any symptoms. The test, created by the biotechnology company Xgenera, works by measuring microRNA—molecules involved in nearly every aspect of how cancer develops—in a blood sample, then uses artificial intelligence to determine whether cancer is present and where in the body it might be located. Early data suggests the test achieves 99 percent accuracy in detecting cancers including lung, gastric, prostate, oesophageal, liver, bladder, ovarian, bowel, pancreatic, breast, bone and soft tissue sarcoma, and a type of brain tumour.
The government has committed £2.4 million in funding through the National Institute for Health and Care Research to move the test into its next phase of development. Around 8,000 patients will participate in what officials are calling the "verification and validation phase"—the stage where researchers gather evidence to support approval for use within the NHS. Health Secretary Wes Streeting announced the backing at an event marking the renaming of a cancer research laboratory in memory of Dame Deborah James, the campaigner and broadcaster who died of bowel cancer in 2022 at age 40.
Streeting framed the investment as part of a broader effort to catch cancer earlier, when treatment is most effective. He acknowledged the toll the disease takes on patients and families, and referenced the long waiting lists that currently delay diagnosis and treatment. The test's potential to diagnose cancer "earlier, faster and cheaper" than existing methods represents, in his view, a significant step toward restoring the UK's cancer survival rates to world-leading levels. He positioned the trial within the government's wider cancer plan, which aims to modernize how the country detects and treats the disease.
Bowel cancer, one of the twelve cancers the test can detect, is the second leading cause of cancer death in the UK and the fourth most common cancer overall. The ability to identify it before symptoms appear could substantially change outcomes for patients. Current screening relies on colonoscopy and other invasive procedures; a simple blood test that could flag the disease earlier would represent a significant shift in how the NHS approaches prevention and early detection.
Professor Lucy Chappell, chief scientific adviser at the Department of Health and Social Care and chief executive of the NIHR, described the test as marking "an exciting new era in cancer detection" with potential for faster, easier, and more effective ways to identify cancers before they become harder to treat. The language reflects cautious optimism—the test has shown promise in initial data, but the verification phase will determine whether those results hold up under the scrutiny required for NHS approval.
Alastair James, the father of Dame Deborah James, attended the announcement and spoke about his daughter's tireless advocacy for cancer awareness and research. He noted that she had participated in various trial treatments herself and would have welcomed the government's investment in cutting-edge research. He echoed her famous public health message—"check your poo"—and framed the test as part of a larger effort to give people affected by cancer more time with their families. The trial thus carries both scientific and personal weight: it is an attempt to validate a promising technology while also honouring the legacy of someone who devoted her final years to pushing the health system toward better detection and treatment.
Citazioni salienti
The key to surviving cancer is catching it as early as possible, so this government is taking the urgent action needed to make sure that happens.— Health Secretary Wes Streeting
Innovations such as the miONCO-Dx blood test offer an exciting new era in cancer detection with the potential for quicker, easier and more effective ways to detect cancers before they become more difficult to treat.— Professor Lucy Chappell, chief scientific adviser at the Department of Health and Social Care
Vuoi la storia completa?
Leggi l'originale su Manchester Evening News ↗
Health & Medicine